Insulin resistance, blood sugar regulation, metabolic syndrome, and body composition
417 artigos
Major study of 30,458 patients finds surgery achieves 28% weight loss vs 10% with GLP-1 drugs, while costing significantly less long-term.
New research highlights the critical need for culturally tailored digital health tools to improve diabetes management outcomes.
New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.
Multi-omic analysis reveals GLP-1 receptor agonists counter aging processes across multiple organ systems and biological pathways.
Deep Dive nos mecanismos da proteína desacopladora 1, controle do sistema nervoso simpático e estratégias terapêuticas para saúde metabólica e longevidade.
New research reveals how SEC16B protein regulates glucose homeostasis by controlling insulin secretion in pancreatic beta cells.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
Two bacterial proteins that sense sulfur compounds unexpectedly regulate nitrate removal, revealing new targets for optimizing wastewater treatment.
Large NHANES study shows TyG-ABSI index better predicts cardiovascular disease and death in metabolic syndrome patients than standard measures.
New review exposes stark disparities in diabetes care across Asia-Pacific, from insulin access to advanced technologies like CGM and pumps.
New cryo-EM structures reveal how LYCHOS protein senses cholesterol levels to regulate mTORC1 signaling, offering drug targets for aging.
Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.
